BR0108659A - Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo - Google Patents

Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo

Info

Publication number
BR0108659A
BR0108659A BR0108659-6A BR0108659A BR0108659A BR 0108659 A BR0108659 A BR 0108659A BR 0108659 A BR0108659 A BR 0108659A BR 0108659 A BR0108659 A BR 0108659A
Authority
BR
Brazil
Prior art keywords
breast cancer
bcmps
antibody
composition
treatment
Prior art date
Application number
BR0108659-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Simon Boyd
Alasdair Craig Stamps
Jonathan Alexander Terrett
Original Assignee
Oxford Glycosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0004576.5A external-priority patent/GB0004576D0/en
Priority claimed from GB0031341A external-priority patent/GB0031341D0/en
Application filed by Oxford Glycosciences filed Critical Oxford Glycosciences
Publication of BR0108659A publication Critical patent/BR0108659A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR0108659-6A 2000-02-25 2001-02-21 Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo BR0108659A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0004576.5A GB0004576D0 (en) 2000-02-25 2000-02-25 Proteins
GB0031341A GB0031341D0 (en) 2000-12-21 2000-12-21 Protein
PCT/GB2001/000748 WO2001062784A2 (en) 2000-02-25 2001-02-21 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
BR0108659A true BR0108659A (pt) 2002-11-05

Family

ID=26243736

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108659-6A BR0108659A (pt) 2000-02-25 2001-02-21 Métodos para tratamento ou prevenção ou profilaxia de câncer de mama, para detecção, diagnóstico e/ou avaliação ou prognóstico quanto ao câncer de mama, para monitoração e/ou estimativa de tratamento do câncer de mama, para identificação da presença ou ausência de células de câncer de mama metastáticas em um amostra biológica e para avaliação ou identificação de compostos, usos de uma ou mais bcmps, de uma composição, de um anticorpo, de ácido nucleico e de um agente que interaja com ou module a atividade de uma ou mais bcmps, vacina, composição, kit e anticorpo

Country Status (14)

Country Link
US (3) US20030130214A1 (enExample)
EP (2) EP1259604A1 (enExample)
JP (1) JP2003524017A (enExample)
KR (1) KR100740761B1 (enExample)
CN (1) CN100384875C (enExample)
AT (1) ATE352311T1 (enExample)
AU (3) AU2001233913A1 (enExample)
BR (1) BR0108659A (enExample)
CA (1) CA2399999A1 (enExample)
DE (1) DE60126248T2 (enExample)
ES (1) ES2279801T3 (enExample)
IL (1) IL151448A0 (enExample)
NZ (1) NZ520967A (enExample)
WO (2) WO2001062784A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
GB0125072D0 (en) * 2001-10-18 2001-12-12 Oxford Glycosciences Uk Ltd Protein
WO2003075014A2 (en) * 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003087834A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. High throughput analysis of recombinant proteins in multi-well plates
GB0208331D0 (en) * 2002-04-11 2002-05-22 Oxford Glycosciences Uk Ltd Proteins
FR2846426B1 (fr) * 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
WO2005029083A1 (en) * 2003-09-22 2005-03-31 Green Peptide Co., Ltd. Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent
EP1693069B1 (en) 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Remedy for solid tumor
JP2007520217A (ja) * 2004-01-27 2007-07-26 コンピュゲン ユーエスエイ，インク． 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
CN104447975A (zh) * 2014-11-18 2015-03-25 深圳市人口和计划生育科学研究所 一种提取人肿瘤细胞膜蛋白的方法
US20180200331A1 (en) * 2015-07-10 2018-07-19 University Of Iowa Research Foundation Bst-2 as a therapeutic target and diagnostic marker for breast cancer growth and metastasis
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR102312897B1 (ko) * 2021-02-26 2021-10-15 에스케이바이오사이언스(주) 목적 단백질의 고수율 정제방법
CN116854782A (zh) * 2023-06-05 2023-10-10 南京大学 一种果糖探针结合蛋白Tom22及其筛选方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007749A1 (en) * 1996-08-23 1998-02-26 Human Genome Sciences, Inc. Novel human growth factors
DE19813839A1 (de) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe
EP1196565A2 (en) * 1999-06-30 2002-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer

Also Published As

Publication number Publication date
JP2003524017A (ja) 2003-08-12
WO2001062914A1 (en) 2001-08-30
KR100740761B1 (ko) 2007-07-19
CA2399999A1 (en) 2001-08-30
AU2001233913A1 (en) 2001-09-03
NZ520967A (en) 2004-04-30
IL151448A0 (en) 2003-04-10
US20070212368A1 (en) 2007-09-13
WO2001062784A3 (en) 2002-01-31
US20030130214A1 (en) 2003-07-10
ATE352311T1 (de) 2007-02-15
US20030099662A1 (en) 2003-05-29
AU3392901A (en) 2001-09-03
EP1257285B1 (en) 2007-01-24
CN1426307A (zh) 2003-06-25
WO2001062784A2 (en) 2001-08-30
CN100384875C (zh) 2008-04-30
KR20030007440A (ko) 2003-01-23
DE60126248T2 (de) 2007-07-05
AU2001233929B2 (en) 2005-09-08
DE60126248D1 (de) 2007-03-15
ES2279801T3 (es) 2007-09-01
EP1257285A2 (en) 2002-11-20
AU2001233929C1 (en) 2006-03-02
HK1056692A1 (zh) 2004-02-27
EP1259604A1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
Seerangaiyan et al. The tongue microbiome in healthy subjects and patients with intra-oral halitosis
Dunkel et al. Reproducibility of microbial mutagenicity assays: II. Testing of carcinogens and noncarcinogens in Salmonella typhimurium and Escherichia coli
BR0115715A (pt) Análise de expressão de ácidos nucleìcos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
BR9814821A (pt) Ensaio de analìtico usando marcas em partìculas
Hernandez et al. A five-year report on experience in the detection of pheochromocytoma
BR0317394A (pt) Uso de nicotinamida n-metiltransferase como um marcador para câncer colorretal
Siemund et al. Establishing aluminium contact allergy
Seidel et al. Modified nucleosides as biomarkers for early cancer diagnose in exposed populations
BRPI0602594A (pt) dispositivo e método para determinação rápida da eficácia de processos de esterilização ou desinfecção
Crunelle et al. Hair ethyl glucuronide as a biomarker of alcohol consumption in alcohol-dependent patients: role of gender differences
Rana Crime investigation through DNA methylation analysis: methods and applications in forensics
Pande et al. Oxidative damage markers as possible discriminatory biomarkers in breast carcinoma
Ponten et al. Patch testing with 2.0%(0.60 mg/cm2) formaldehyde instead of 1.0%(0.30 mg/cm2) detects significantly more contact allergy
CA3047060A1 (en) Methods of determining colorectal cancer status in an individual
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
BRPI0612169A2 (pt) métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação
BRPI0809958B8 (pt) conjunto de esferas para a detecção de uma cepa de hpv e/ou para diferenciação entre duas ou mais cepas de hpv, método para a preparação do referido conjunto de esferas, método para o diagnóstico de infecção por hpv, método para determinação do risco de um indivíduo humano desenvolver uma doença associada a uma ou mais cepas de hpv e par de iniciadores para amplificação de oligonucleotídeo direcionado ao hpv oncogênico
ATE553112T1 (de) Ttk in der diagnose und als therapeutisches target bei krebs
Richards-Rios et al. Changes in the faecal microbiome of pied tamarins (Saguinus bicolor) associated with chronic, recurrent diarrhoea and weight loss
BR9910372A (pt) Processos para detectar tecido canceroso, e, para realizar um procedimento cirúrgico para remover uma lesão cancerosa de um tecido
MX2024000571A (es) Prueba basada en hisopo oral para detectar varios estados de una enfermedad en gatos domesticos.
Hegde et al. Relating tooth‐and blood‐lead levels in children residing near a zinc–lead smelter in India
Martin Complex mixtures that may contain mutagenic and/or genotoxic components: a need to assess in vivo target-site effect (s) associated with in vitro-positive (s)
ATE155689T1 (de) Aktivätsmessungen des amylin
Jacobs et al. An in vitro model for detecting skin irritants: methyl green-pyronine staining of human skin explant cultures

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.